drugset
drugset / Trial / NCT03984578

Window of Opportunity Study in Colorectal Cancer

NCT03984578 ↗

Phase 2 Completed 33 enrolled National Cancer Centre, Singapore Merck Sharp & Dohme LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a window of opportunity translational study investigating the use of pre-operative pembrolizumab and chemotherapy or chemoradiotherapy in non-metastatic colorectal cancer.

Timeline

Start
2019-06-12
Primary completion
2025-02-28
Completion
2025-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Capecitabine Small molecule 825 mg/m2 Oral
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background fluorouracil Small molecule 225 mg/m2 —

Indications

colorectal cancer